ATE307605T1 - Nichttoxische mutanten pathogener gram-negativer bakterien - Google Patents

Nichttoxische mutanten pathogener gram-negativer bakterien

Info

Publication number
ATE307605T1
ATE307605T1 AT96942080T AT96942080T ATE307605T1 AT E307605 T1 ATE307605 T1 AT E307605T1 AT 96942080 T AT96942080 T AT 96942080T AT 96942080 T AT96942080 T AT 96942080T AT E307605 T1 ATE307605 T1 AT E307605T1
Authority
AT
Austria
Prior art keywords
gram
htrb
negative bacterial
mutant
wild type
Prior art date
Application number
AT96942080T
Other languages
English (en)
Inventor
Michael A Apicella
Melvin G Sunshine
Na-Gyong Lee
Rasappa Arumugham
Bradford W Gibson
Original Assignee
Univ Iowa Res Found
Univ California
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37854778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE307605(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa Res Found, Univ California, Wyeth Corp filed Critical Univ Iowa Res Found
Application granted granted Critical
Publication of ATE307605T1 publication Critical patent/ATE307605T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96942080T 1995-12-01 1996-11-27 Nichttoxische mutanten pathogener gram-negativer bakterien ATE307605T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/565,943 US6887483B2 (en) 1995-12-01 1995-12-01 Non-toxic mutants of pathogenic gram-negative bacteria
PCT/US1996/018984 WO1997019688A1 (en) 1995-12-01 1996-11-27 Non-toxic mutants of pathogenic gram-negative bacteria
US09/077,572 US7005129B1 (en) 1995-12-01 1996-11-27 Non-toxic mutants of pathogenic gram-negative bacteria

Publications (1)

Publication Number Publication Date
ATE307605T1 true ATE307605T1 (de) 2005-11-15

Family

ID=37854778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96942080T ATE307605T1 (de) 1995-12-01 1996-11-27 Nichttoxische mutanten pathogener gram-negativer bakterien

Country Status (10)

Country Link
US (5) US6887483B2 (de)
EP (1) EP0876150B2 (de)
JP (1) JP2001500363A (de)
AT (1) ATE307605T1 (de)
AU (1) AU710933B2 (de)
CA (1) CA2238640C (de)
DE (1) DE69635352T2 (de)
DK (1) DK0876150T4 (de)
ES (1) ES2248825T3 (de)
WO (1) WO1997019688A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1998033923A1 (en) * 1997-01-30 1998-08-06 Imperial College Of Science, Technology & Medicine MUTANT msbB or htrB GENES
ES2301181T3 (es) 1997-08-21 2008-06-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas.
CN1253551C (zh) 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CA2264970A1 (en) * 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6645503B1 (en) * 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
ATE518874T1 (de) * 1999-11-15 2011-08-15 Oncothyreon Inc Synthetische lipid-a analogen und verwendungen davon
HU230847B1 (en) * 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
EP1341546B1 (de) * 2000-10-06 2011-09-21 The Symbio Herborn Group GmbH u.Co Kyberdrug als autovakzine mit immunregulierenden wirkungen
US7164008B2 (en) 2003-11-17 2007-01-16 University Of Iowa Research Foundation Isolated complexes of endotoxin and MD-2
CA2587493A1 (en) * 2004-11-30 2006-06-08 Aeras Global Tb Vaccine Foundation Bacterial packaging strains usefuel for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof
BRPI0519923A8 (pt) * 2004-12-17 2018-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Vws polipeptídeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-0-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-0-desacilado, vacina, e, método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo, e, para induzir uma resposta imune contra bordetella.
US8088396B2 (en) 2006-03-01 2012-01-03 University Of Iowa Research Foundation Isolated complexes of endotoxin and modified MD-2
US8137682B2 (en) 2006-09-20 2012-03-20 University Of Iowa Research Foundation Isolated complexes of covalently cross-linked endotoxin and modified MD-2
CA2761924C (fr) 2009-05-14 2017-10-31 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
WO2010130896A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
GB0917002D0 (en) * 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US11052142B2 (en) 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
US20160120967A1 (en) 2013-06-04 2016-05-05 Petr Gennadievich Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE940698L (en) 1984-04-05 1985-10-05 Univ Missouri Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CN1083524A (zh) * 1992-07-06 1994-03-09 哈佛大学校长及研究员协会 作为霍乱疫苗缺失突变体
US5997881A (en) 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
AU762369B2 (en) * 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria

Also Published As

Publication number Publication date
US6887483B2 (en) 2005-05-03
US7510717B2 (en) 2009-03-31
AU710933B2 (en) 1999-09-30
CA2238640C (en) 2002-09-17
DE69635352D1 (de) 2005-12-01
EP0876150A4 (de) 2002-01-30
US7226588B2 (en) 2007-06-05
WO1997019688A1 (en) 1997-06-05
US20070048331A1 (en) 2007-03-01
US20090285844A1 (en) 2009-11-19
US20050048076A1 (en) 2005-03-03
JP2001500363A (ja) 2001-01-16
DK0876150T4 (da) 2009-08-10
DE69635352T2 (de) 2006-07-27
ES2248825T3 (es) 2006-03-16
DK0876150T3 (da) 2006-01-16
US20070104736A1 (en) 2007-05-10
EP0876150A1 (de) 1998-11-11
CA2238640A1 (en) 1997-06-05
AU1124697A (en) 1997-06-19
EP0876150B1 (de) 2005-10-26
EP0876150B2 (de) 2009-04-29
US7005129B1 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
ATE307605T1 (de) Nichttoxische mutanten pathogener gram-negativer bakterien
Ehrenfeld et al. Identification of pheromone-induced surface proteins in Streptococcus faecalis and evidence of a role for lipoteichoic acid in formation of mating aggregates
Govan et al. Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid form to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro
Zaidi et al. Lipopolysaccharide outer core is a ligand for corneal cell binding and ingestion of Pseudomonas aeruginosa.
Van Der Ley et al. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity
Finkelstein et al. Vibrio cholerae hemagglutinin/protease, colonial variation, virulence, and detachment
Baehni et al. Leukotoxic activity in different strains of the bacterium Actinobacillus actinomycetemcomitans isolated from juvenile periodontitis in man
Carsiotis et al. Flagella of Salmonella typhimurium are a virulence factor in infected C57BL/6J mice
EP0184086B1 (de) Nichtrevertierende Salmonella-Lebendimpfstoffe
Mitsuhashi The R factors
Michel et al. Acanthamoeba from human nasal mucosa infected with an obligate intracellular parasite
AU6033299A (en) Compositions of beta-glucans and specific igiv
AU559550B2 (en) Vaccines
Zambon et al. Molecular genetic analysis of Actinobacillus actinomycetemcomitans epidemiology
AU1915995A (en) Active immunization using a siderophore receptor protein
Oudbier et al. Genotypical variation of Campylobacter pylori from gastric mucosa
Kong et al. Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar typhimurium msbB mutant
Steinert et al. Studies on the uptake and intracellular replication of Legionella pneumophila in protozoa and in macrophage-like cells
US6589771B1 (en) Methods for arousing dormant bacteria
Takai et al. Effect of growth temperature on maintenance of virulent Rhodococcus equi
BR9608204B1 (pt) composiÇço nematocida, e, processo para controlar nematàdeos patogÊnicos para planta.
Hatten et al. Intracellular Production of Brucella L Forms I. Recovery of L Forms from Tissue Culture Cells Infected with Brucella abortus
LINDBERG Bacterial Virulence Factors-with Particular Reference to Sa/mone//a Bacteria
John Roche et al. Phase variation of Haemophilus influenzae lipopolysaccharide: characterization of lipopolysaccharide from individual colonies
Khattak et al. Is Bordetella pertussis clonal?

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0876150

Country of ref document: EP

RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties